Loading clinical trials...
Loading clinical trials...
Imaging of Ventricular Reversed Remodeling After Double Lung Transplantation in Patients With Pulmonary Arterial Hypertension
The investigators will evaluate ventricular reversed remodelling after double lung transplantation (LTX) in patients with pulmonary arterial hypertension (PAH), measured with cardiac magnetic resonance imaging (MRI). Reversed remodelling will be compared with control patients without PAH (e.g. Cystic Fibrosis) who will also undergo LTX.
In this study, pre-LTX and six-months post-LTX measurements will be compared with each other and between the primary and control group. Pre- and post-LTX measurements include: Past medical history: Including basic diagnosis; interventions, surgery and transplant related complications (re-operations, hospitalizations, infections) and medication history; These data will be collected by studying the medical files including surgical reports. Present medical history: Including NYHA class. Physical examination: Including length and weight. Cardiac Magnetic Resonance Imaging: * Ventricular volume, function and mass measurements * Flow measurements of the pulmonary artery and aorta * Disease specific measurements (e.g. septal bowing, RV trabecularisation, etc.) * T1-mapping Transthoracic Echocardiography Resting ECG: Disease specific electrophysiological findings (e.g. QRS-duration, right bundle branch block). Laboratory evaluation: * NT-pro-BNP * eGFR * Remaining serum will be stored.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University Medical Center Groningen
Groningen, Netherlands
Start Date
March 1, 2015
Primary Completion Date
August 1, 2019
Completion Date
August 1, 2019
Last Updated
August 26, 2019
17
ACTUAL participants
Lead Sponsor
University Medical Center Groningen
Collaborators
NCT06649110
NCT07218029
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06481852